DAFNA Capital Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

DAFNA Capital Management’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-74,953	Closed	-$980K	–	86
2022 Q3	$980K	Sell	74,953 -32,700	-30%	-$495K	0.26%	55
2022 Q2	$1.38M	Hold	107,653	–	–	0.38%	55
2022 Q1	$1.64M	Buy	107,653 +27,168	+34%	+$424K	0.43%	58
2021 Q4	$1.43M	Buy	80,485 +15,000	+23%	+$288K	0.36%	56
2021 Q3	$1.38M	Buy	65,485 +34,983	+115%	+$770K	0.37%	60
2021 Q2	$601K	Buy	30,502 +20,502	+205%	+$480K	0.13%	80
2021 Q1	$291K	Buy	+10,000	New	+$280K	0.07%	85
2019 Q3	–	Sell	-6,265	Closed	-$92K	–	95
2019 Q2	$92K	Buy	+6,265	New	+$91.7K	0.03%	83

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DAFNA Capital Management's NGM Position: Q4 2022 in Review

DAFNA Capital Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2022, closing a stake of 74,953 shares — an estimated $980K sold.

DAFNA Capital Management first reported a position in NGM in Q2 2019 and held it in 8 quarters. The position peaked at $1.64M in Q1 2022. 125 funds tracked by Wall St. Rank hold NGM as of Q4 2022.

DAFNA Capital Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
DAFNA Capital Management sold 74,953 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $980K.
DAFNA Capital Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 8 quarters.
DAFNA Capital Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1.64M in Q1 2022.
125 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on DAFNA Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.